Has Suma Sri Chennapragada received payments from drug or device companies?

Yes. Drug and device makers reported $1,632 in general payments to Suma Sri Chennapragada across 57 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Suma Sri Chennapragada did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Suma Sri Chennapragada come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Suma Sri Chennapragada

Hematology & Oncology · Fort Smith, ARNPI 1831742154

Payments from drug & device makers

$1,632in general payments, 2019–2025

Across 57 payments — averaging $28.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

AstraZeneca$260
AbbVie$255
Daiichi Sankyo Inc.$239
Sanofi$132
Tempus AI, Inc$112
Novartis$84
plus $549 from 15 others

What the payments were for

Food & beverage$1,48891%
Education$1439%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
AstraZeneca(2 entities)	6	$260
AbbVie	9	$255
Daiichi Sankyo Inc.	7	$239
Sanofi	2	$132
Tempus AI, Inc	2	$112
Novartis	4	$84
GSK	4	$70
Pfizer	3	$58
Takeda Pharmaceuticals U.S.A., Inc.	2	$56
Johnson & Johnson	3	$54
Regeneron Healthcare Solutions, Inc.	2	$47
Recordati_rare_diseases_inc.	2	$38
Merck	2	$37
Astellas Pharma US Inc	2	$32
Geron Corporation	1	$30
Jazz Pharmaceuticals Inc.	1	$27
ADC Therapeutics America, Inc.	1	$26
Syndax Pharmaceuticals, Inc.	1	$24
Beone Medicines USA, Inc.	1	$19
Bayer	1	$16
Bristol Myers Squibb	1	$15

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

LYNPARZA$125

How this compares

$1,632 in reported general payments places this provider in the 25th percentile of 92 hematology & oncology providers in Arkansas.

See all hematology & oncology providers in Arkansas →

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
VenclextaVenetoclax	13	$129,588
EliquisApixaban	28	$18,453
Ondansetron OdtOndansetron	25	$1,142
ValacyclovirValacyclovir Hcl	16	$616
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen	37	$605
Oxycodone Hcl	29	$579
Morphine Sulfate ErMorphine Sulfate	23	$520
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen	11	$310
Anastrozole	21	$282
Dexamethasone	17	$260
Gabapentin	24	$254
Pantoprazole Sodium	22	$198
Potassium Chloride	20	$192
Acyclovir	12	$77
Prochlorperazine Maleate	12	$72

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

Company	Paid to this provider	Part D cost of their drugs
AbbVieVenclexta	$255	$129,58813 claims
PfizerEliquis	$58	$18,45328 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 25th percentile of 92 hematology & oncology providers in Arkansas.

Other hematology & oncology in Fort Smith

Isam Abdel-KarimFort Smith$658K
Humdum DurraniFort Smith$324K
Narender GorukantiFort Smith$20K
Tony FlippinFort Smith$18K
Varant ArzoumanianFort Smith$7K
Daniel MackeyFort Smith$6K
Aswanth ReddyFort Smith$5K
John WellsFort Smith$5K
Joseph BeckFayetteville$33.8M
Eric SchaeferFayetteville$5.2M

See the full list for Arkansas →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →